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Localization of the complement regulatory proteins in the normal
human kidney. The kidney is an organ where complement-mediated
tissue injuries take place by various stimuli. To assess how the kidney
is protected from the autologous complement attack, comparative
localization of decay accelerating factor (DAF), membrane cofactor
protein (MCP) and 20 kDa homologous restriction factor (HRF2O) was
studied in the normal human kidney. Specific monoclonal antibodies to
DAF, MCP and HRF2O were used for the study. Studies by immuno-
fluorescence and immunoelectron microscopy showed that the distri-
bution of each protein in the kidney was complementary to each other
in most parts. MCP and HRF2O were clearly seen in the glomerular
capillaries, while DAF was only faintly observed. Juxtaglomerular
apparatus was abundant in DAF and MCP but not in HRF2O. HRF2O
was most strongly expressed in the peritubular capillaries where MCP
was not detectable. Basolateral membranes of the proximal tubules and
collecting ducts expressed MCP strongly, while there was no expres-
sion of DAF in the proximal tubules. Interestingly, both DAF and MCP,
which inhibit complement activation at C3/C4 level, were not expressed
in the apical portion of the tubular cells including proximal tubule brush
border. In contrast, HRF2O was expressed on the apical part of the
tubules. Medullary interstitium strongly expressed MCP but not DAF.
Based on these observations, we conclude that each segment of the
kidney is protected from the complement attack by the different
combination of complement regulatory proteins. We speculate that the
tubular cells might be fragile when complements are activated inside the
tubular lumen, because there is no expression of complement regula-
tory proteins which inhibit C3 convertase.
The complement system plays an important role in self
defense. Its cascade is activated not only by antigen-antibody
interaction but also by non-immunological stimuli [1], resulting
in release of anaphylatoxins [2] or the formation of membrane
attack complex (MAC) on the target cell membrane. The intact
host cells, however, are protected from indiscriminate attack of
the autologous complement system. This is mediated in part by
a relatively non-specific self-recognition system of the alterna-
tive pathway [3] and in part by specific complement regulatory
proteins present on the cell membranes [4].
Mechanisms by which the kidney is injured by the comple-
ment system have been studied extensively. It is now clear that
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the kidney is always under the menace of complement attack.
The glomerulus has a function and structure by which macro-
molecules, including immune complexes, can be easily trapped
and thus activate the complement system. It has been shown in
experimental glomerulonephritis that complement depletion by
cobra venom factor ameliorated immune-mediated glomerular
injuries [5]. Tubules are directly exposed to various comple-
ment components in proteinuric condition. Since the brush
border of proximal tubules can activate alternate pathways of
complement both in tissue section [61 and in cells in culture [7],
the presence of complement components in the tubular lumen
may lead to complement attack on the tubular cells [8]. In
addition, ammonium concentration is markedly high in renal
medulla [9]. Since ammonium can activate C3 by disrupting the
internal thioester bond [10, 11], there is possibility that the
alternate pathway is spontaneously activated in the renal me-
dulla. Ammonium production is markedly increased after pro-
tein diet [12] and is inhibited by the administration of sodium
bicarbonate [13]. In an experimental model, inhibition of am-
monium production by sodium bicarbonate protected the kid-
ney from progressive renal failure [13]. Thus, ammonium seems
to play an important role in the progression of renal disease
through mediation of complement activation. The addic condi-
tion seen in renal medulla may also activate C3. All of these
events might cause serious renal injury if there is no inhibitory
mechanism against complement activation.
Recently, a family of complement regulatory proteins present
on the cell membranes has been identified in the human, and
they are widely distributed not only on the membranes of blood
cells but also in the vascular endothelum and extra-vascular
tissues [14-17]. These include decay accelerating factor (DAF
or CD55) [18], membrane cofactor protein (MCP or CD46) [19]
and 20 kDa homologous restriction factor (HRF2O or CDS9) [20,
21]. DAF and MCP inhibit the complement activation cascade
at C3 convertase level, and HRF2O inhibits the formation of
membrane attack complexes (MAC). Although localization of
these molecules in the kidney has been reported [14—16, 22—25],
the precise comparative localization has not been studied yet.
In this study, we investigated comparative localization of DAF,
MCP and HRF2O in normal human kidneys in an attempt to
evaluate the role of each molecule in the defense against
autologous complement attack.
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Methods
Kidney specimens
Specimens from normal human kidneys were studied. They
were prepared from the normal portion of nephrectomized
kidneys of four patients who had renal tumors. These speci-
mens were confirmed as histologically normal by light micro-
scopic examination.
Antibodies
Mouse monoclonal antibodies against human DAF (IA1O)
and MCP (M75) were gifts from T. Kinoshita (Department of
Immunochemistry, Research Institute for Microbial Deseases,
Osaka University School of Medicine, Suita, Japan) and T.
Seya (Department of Immunology, The Center for Adult
Deseases, Osaka, Japan), respectively. A monoclonal antibody
against human HRF2O (1F5) was prepared by Okada and
co-workers. These monoclonal antibodies inhibit the function
of corresponding regulatory molecules. Specificity and property
of JAb, M75 and iFS have been previously reported [20, 26,
27]. IA1O recognizes a 70 kDa human DAF molecule by
Western blot analysis. JAb, when used in combination with
11H6 (another anti-DAF monoclonal antibody), inhibited the
function of DAF by 78% [261. M75 immunoprecipitates human
MCP, and it blocks MCP factor 1-cofactor activity by 70% [271.
1F5 recognizes HRF2O and it blocks the function of HRF2O in
a dose-dependent manner [20]. All of these antibodies belonged
to mouse IgGl subclass.
To identify the precise segments of tubules and collecting
ducts expressing these three antigens, double immunofluores-
cence staining method was employed using the following anti-
bodies. One is goat antibodies against human Tamm Horsfall
protein (THP or uromucoid) (SEROTEC Ltd., Oxford, UK).
THP is present in the distal tubules of cortex and outer medulla
[28, 291. Others are serum obtained from a patient with anti-
tubular basement membrane (anti-TBM)-mediated tubulointer-
stitial nephritis [30, 31], and a monoclonal antibody (H79B 12)
reactive with the nephritogenic 54 kDa antigen of bovine TBM
[31]. Both predominantly bound to the proximal TBM of the
normal human kidney by indirect immunofluorescence.
Immunofluorescence studies
Small pieces of kidney cortex and medulla were embedded in
OCT compound (Miles Inc., Elkhart, Indiana, USA) and were
snap-frozen in liquid nitrogen. Frozen tissues were cut by a
cryostat and 2-sm thick sections were obtained. They were
fixed in acetone for 15 minutes at room temperature. Studies
were performed by an indirect immunofluorescence (IF) tech-
nique [32]. For the staining of DAF, MCP, HRF2O, and
proximal TBM, the sections were washed with PBS and then
incubated at room temperature for 15 minutes with one of
mouse monoclonal antibodies against complement regulatory
proteins. As a control, the sections were incubated with an
irrelevant monocbonal antibody of IgGl subclass, H38F9E6A6.
The optimal concentrations of IA 10, M75, 1F5 and H79B 12
were 10 JLg/ml, 2.5 g/m1, 12 tg/ml and 10 gIml, respectively.
The sections were washed three times with PBS and they were
then incubated with fluorescein isothiocyanate (FITC)-labeled
rabbit anti-mouse IgG antibodies (Zymed Laboratories, San
Francisco, California, USA) absorbed with normal human
Fig. 1. Immunofluorescence micrographs showing localization of DAF
(a), MCP (b) and HRF2O (c) in the glomerulus and efferent arteriole
(EA). (a, b, C: x200)
serum. For the double immunofluorescence staining of THP
and complement regulatory protein, the sections were first
stained for one of the complement regulatory proteins as
described above. They were then incubated with goat anti-
human THP antisera (diluted at 1:250) followed by the incuba-
tion with rhodamine-labeled rabbit anti-goat IgG (Cappel, West-
chester Pennsylvania, USA) absorbed with normal human
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Fig. 2. Double immunofluorescence micrographs. Two pairs of figures (a vs. b, and c vs. d) indicate the same tissue sections. (a and C): The
localization of MCP in the cortex. (b and d): The localization of THP and proximal TBM, respectively. Arrows indicate macula densa. These
pictures show an example how each nephron segment is identified. The segment which are most strongly stained for MCP is not reactive with anti-
THP and anti-proximal TBM antibodies. Thus the segments most strongly stained for MCP are identified as collecting ducts. Segments reactive
with antj-THP or with anti-proximal TBM are identified as distal tubules or proximal tubules, respectively. Abbreviations are: G, glomerulus; P,
proximal tubule; D, distal tubule; C, collecting duct. (a, b, c, d: X 100)
serum. For the double immunofluorescence staining for TBM
and complement regulatory proteins, frozen sections were first
treated with 0.1% streptoavidin (Gibco BRL, Gaithersburg,
Maryland, USA) for 10 minutes and 0.01% biotin (Vector
Laboratories, Burlingame, California, USA) for 10 minutes at
room temperature. They were then incubated with an antibody
against one of the complement regulatory proteins followed by
the incubation with rhodamine-labeled rabbit anti-mouse IgG
(Cappel). After washing with PBS, sections were treated with
normal mouse serum (1:100 dilution). They were then incubated
with biotinylated H79B 12 or rhodamine-labeled human anti-
TBM antibodies followed by the incubation with FITC-labeled
streptoavidin (Vector Laboratories). After the final wash with
PBS, all the sections were mounted with medium containing
p-phenylenediamine [33] and examined by an Olympus BH-2
epifluorescence microscope. Since peritubular capillaries were
most strongly stained by lFS, we assigned the staining intensity
of the peritubular capillaries as 3 + and the intensity of immu-
nofluorescence staining was graded from 0 (negative) to 3+
accordingly. Similarly, the intensity of immunofluorescence
staining for DAF ofjuxtaglomerular apparatus and that of MCP
of cortical collecting tubules and smooth muscle cells of afferent
arterioles were assigned 3+. The staining intensity for DAF and
MCP of the other portion of the kidney was graded from 0
(negative) to 3+ accordingly.
Immunoelectron microscopy (JEM) studies
To see the localization of MCP and HRF2O in the kidney
cortex, IEM studies were carried out according to a method
previously described [32]. IEM studies were not performed for
DAF because immunoreactivity of tissue DAF with IA1O was
lost by various fixation methods [22]. Small blocks of normal
human kidney were fixed with periodate lysine paraformalde-
hyde (PLP) fixative [34] for four hours at 4°C, washed with 10
mM PBS containing 10%, 15% and 20% sucrose. After final
wash in PBS containing 20% sucrose and 5% glycerol for one
hour, blocks were embedded in OCT compound and frozen in
liquid nitrogen. Six-micrometer thick frozen sections were
mounted on albumin-coated slides and treated with PBS con-
taining NaBH4 (50 mg/dl) for 40 minutes at room temperature.
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minutes at 37°C before incubating the sections with first anti-
bodies [35, 361.
Results
Cortex
Glomerulus. HRF2O was moderately expressed in glomerular
capillaries and in Bowman's capsule, and it was weakly ex-
pressed in the juxtaglomerular apparatus. In contrast, DAF and
MCP were moderately to strongly expressed in juxstaglomeru-
lar apparatus (not shown). DAF and MCP were weakly ex-
pressed in glomerular capillaries and Bowman's capsule (Fig.
1).
Tubule. In the cortex proximal tubules were identified by
H78B 12 and distal tubules by anti-THP serum. Cortical collect-
ing ducts or connecting tubules were identified as segments
which did not react with these two antibodies (Fig. 2). There
was no expression of DAF in the proximal and distal tubules.
Basal membrane of the cortical collecting ducts only weakly
expressed DAF (figure not shown). MCP was most strongly
expressed in basolateral membranes of cortical collecting ducts,
and moderately in the same area of proximal tubules (Fig. 3a).
In contrast to these areas, apical portion (brush border) of
proximal tubules did not express MCP (Figs. 3a and 4 a, b).
Distal tubules weakly expressed MCP. HRF2O was most
strongly expressed in the peritubular capillaries (Fig. 3b), while
MCP was absent in this area (Fig. 3a). HRF20 was weakly
expressed in the brush border of proximal tubules (Figs. 3b and
4 c, d).
Vessels. Smooth muscle cells of arterioles strongly expressed
DAF and MCP, while expression of HRF2O was much weaker
in the same area. Endothelium of arterioles, however, ex-
pressed HRF20 moderately but not DAF or MCP (Fig. 1).
Fig. 3. Immunofluorescence micrographs showing localization of
MCP (a) and HRF2O (b) in the proximal tubules and peritubular
capillaries. (a, b: x400)
After washing with PBS containing 10% sucrose, sections were
incubated with normal horse serum for 30 minutes at room
temperature, and then incubated with the first antibody (M75 or
1F5) overnight at 4°C. For the detection of mouse IgG sections
were first incubated with biotinylated horse anti-mouse IgG and
then with peroxidase labeled streptoavidin (Vectastain ABC
Kit, Vector Laboratories). The sections were post-fixed with
2.5% glutaraldehyde and incubated in 0.5 M Tris-HCI buffer
containing 0.02% diaminobenzidine tetrahydrochloride for 30
minutes at room temperature. They were incubated for another
Ito 2 minutes in 0.05% H202 and were further fixed with 0s04.
They were then flat embedded in Epon 812. Ultra thin sections
were stained with lead for 15 seconds and were observed by a
JEOL-100 CX electron microscopy (JEOL Company Ltd.,
Tokyo, Japan).
PIPLC treatment
To analyze how DAF, MCP and HRF2O are anchored to the
cell membrane of the kidney, we treated the sections with 4
mg/mi phosphatidylinositol specific phospholipase C (PIPLC,
Toa Gousei Chemical Industry Co. Ltd., Tokyo, Japan) for 60
Outer medulla
Outer stripe. Localization of DAF, MCP and HRF2O in each
segment of the kidney was similar to that observed in the
cortex.
Inner stripe. Vascular bundles are fully developed in this
area. Although vascular walls of descending vasa recta were
strongly stained for DAF, MCP and HRF2O, localization of
HRF2O was more confined to the endothelial aspects of vascu-
lar walls. In contrast, ascending vasa recta expressed only
HRF2O but not DAF or MCP (Fig. 5). Nephron segments
present in the inner stripe of the kidney include distal tubules
(straight part), collecting ducts and thin limbs of Henle. DAF
was observed in the basal membranes of collecting tubules but
not in distal tubules or thin limbs of Henle. DAF was moder-
ately expressed in peritubular capillaries (not shown). MCP was
strongly expressed in the collecting tubules, but it was only
faintly expressed in the distal tubules, thin limbs or peritubular
capillaries. MCP was also present in the interstitium (not
shown). HRF2O was strongly expressed in the peritubular
capillaries. It was weakly expressed in the apical part of distal
tubules and in the surface of collecting ducts (not shown).
Inner medulla
DAF was present in the vessels and the basal membrane of
collecting ducts. It was not observed in most part of interstitium
(lipid laden interstitial cells or type 1 medullary interstitial cells;
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Fig. 4. Immunoelectron microscopy showing localization of MCP (a, b) and HRF2O (c, d) in the proximal tubules. Note that MCP is moderately
expressed in the basolateral membrane of the proximal tubules while it is not present in the brush border. HRF2O is weakly expressed in the tubular
brush border. Symbols are: arrows, brush border; small arrowheads, TBM; large arrowheads, lateral membrane. (a: x2,600, b: X5,000, c: x2,000,
d: X6,300)
Fig. 6a). MCP was strongly expressed in the interstitium as well less prominent. By way of contrast, staining for MCP was not
as in the baso-lateral membrane of collecting tubules and in the affected at all by PIPLC treatment.
vessels (Fig. 6b). HRF2O was again strongly expressed in the
capillaries. It was weakly expressed in the interstitium and in Discussion
the collecting ducts (Fig. 6c). In the present work we studied comparative localization of
These data are summarized in Table I. DAF, MCP and HRF2O in the normal human kidney in order to
assess how the kidney is protected from autologous comple-
PIPLC treatment ment attack. These molecules are known to be widely distrib-
By PIPLC treatment, the staining for HRF2O became barely uted throughout the body, while other regulatory proteins such
detectable. The influence of PIPLC treatment on the staining as complement receptor I and 2 (CR1 and CR2) are basically
for DAF was also observed although the effect was relatively limited to blood borne cells [37]. Thus it is thought that DAF,
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Fig. 5. Immunofluorescence micrographs showing localization of DAF
(a),MCP (b), andHRF2O (c) in the area of vascular bundles of the inner
stripe. Abbreviations are: D, discending vasa recta; A, ascending vasa
recta. (a, b, C: X400)
MCP and HRF2O play major roles in the protection against
complement attack on the kidney cells.
From the present work we obtained three new findings. First,
DAF, MCP and HRF2O have different localizations in the
normal human kidney. Although there was limitation in the
Fig. 6. Immunofluorescence micrographs showing localization of DAF
(a), MCP (b) and HRF2O (c) in the inner medulla. Abbreviations and
symbols are: C, collecting duct; V, vessels; thin arrows, peritubular
capillaries; thick arrows, arterioles. (a, b, c: x400)
quantitation of each molecule, apparently there was difference
in the staining intensity in the different segment of the nephron.
HRF2O was most widely distributed in the kidney. MCP and
DAF seemed to compensate with each other. From the view-
point 'f defense against complement attack, this observation is
Ichida et a!: Complement regulatory proteins in the kidney 95
Table 1. Summary of localization of complement regulatory proteins
in the normal human kidney
Segment
DAF
(CD55)
MCP
(CD46)
HRF2O
(CD59)
Glomerular capillaries +1— + — ++ + +
Bowman's capsule +I + ÷ — ++
Juxtaglomerular apparatus + + + + + +
Proximal tubules
Basolateral membrane — ++ +1—
Bush border — — +
Distal tubules
Basolateral membrane +1— + +
Apical membrane — — +
Collecting ducts
Connecting tubules
Basolateral membrane +
(basal
membrane)
+ +++
(inner medulla
cortex)
+1—
Apical membrane — — +1—
Intermediate tubules — +1— +1—
(Thin limb of Henle)
Peritubular capillaries + — + + +
Arterioles
Smooth muscle cells + + + + + +
Endothelium +1— +1— ++ +++
Vascular bundles
Descending vasa recta ++ ++ - +++ +++
Ascending vasa recta — — + — ++
Medullary interstitium — + + +
(Interstitial cells)
reasonable because each segment regulates C3 convertase
activity either by DAF or MCP, and inhibits formation of MAC
by HRF2O. Since these two steps are most important in the
regulation of alternative pathway of complement and the sub-
sequent cellular damage, most structures of the normal kidney
are protected at these two steps. Second, apical portion of the
proximal tubular cells were free of DAF and MCP, both
regulators of C3 convertase. Our findings concerning DAF
localization are consistent with those of Cosio and coworkers
using biopsy specimens [221. Although Medof showed positive
staining for DAF in the tubular epithelial cells of autopsy
kidneys [14], expression of DAF in the tubular brush border
was not well described. Our observation is interesting because
tubular brush border is reported to activate the alternate
pathway of complement [61. It is also reported that proteinuria
causes tubular damage in rats [381; there is evidence of com-
plement activation in the proximal tubular epithelium in pa-
tients with nonselective proteinuria [39]. One of the reasons
why complements are activated in the proximal tubule brush
border might be related to the absence of both DAF and MCP
in this portion. Once C3 is activated by any stimuli, there will be
[urther activation of complements through the amplification
system of C3 convertase because there is no inhibitory protein
n the proximal tubule brush border. Third, MCP and HRF2O
were intensely localized in the interstitium between collecting
Jucts and vessels in the inner medulla. Since the predominating
ells in this area are lipid laden interstitial cells (or type 1
rnedullary interstitial cells), it was speculated that these cells
xpressed MCP and HRF2O. Although the physiological role of
Lipid laden interstitial cell is unknown, these cells are also
protected from complement attack by the presence of comple-
ment regulatory proteins.
Finally the present study indicates that, like in blood cells,
HRF2O and DAF are present on the surface of the cell mem-
brane by phosphatidylinositol anchoring, but MCP is not an-
chored by glycophosphatidylinositol in the normal human kid-
ney. The difference of sensitivity of HRF2O and DAF to PIPLC
treatment is thought to be dependent on the cells on which each
molecule is expressed [20, 40, 41]. It is further suggested that
the different sensitivity of glycolipid-anchored acetylcholines-
terases results from presence or absence of acylation of a
inositol ring in the glycolipid anchor [42]. The exact nature of
the glycophosphatidylinositol anchoring of DAF and HRF2O in
the kidney cells should be further investigated.
In conclusion, the present work demonstrates that the normal
human kidney is abundant in the membrane-associated comple-
ment regulatory proteins, and that most segments of the normal
human kidney are protected from autologous complement at-
tack by different combination of three types of complement
regulatory proteins.
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